Searchable abstracts of presentations at key conferences in endocrinology

ea0029p785 | Endocrine tumours and neoplasia | ICEECE2012

Mitochondrial respiratory chain defects: a novel molecular mechanism of Mitotane for treatment of Adrenocortical Carcinoma

Hescot S. , Slama A. , Paci A. , Remy H. , Chadarevian R. , Trabado S. , Lombes A. , Young J. , Baudin E. , Lombes M.

Mitotane (o,p’DDD) represents the most effective treatment of adrenocortical carcinoma (ACC). However, molecular mechanisms of mitotane action remain poorly understood. Mitochondrial (mt) impact of mitotane has previously been suggested but not yet fully validated. We investigated functional consequences of mitotane exposure on mitochondrial steroidogenesis, respiratory chain activity and biogenesis, using human adrenocortical secreting H295R and non-secreting SW13 cells....

ea0070aep163 | Bone and Calcium | ECE2020

Case report: Refractory hypercalcemia due to a pancreatic neuroendocrine tumor misdiagnosed as adenocarcinoma

Hage Mirella , Hescot Ségolène , Asnacios Amani , Bakopoulou Sophia , Cazabat Laure , Houillier Pascal , Jean Francois Emile , Raffin-Sanson Marie-Laure

Background: Hypercalcemia is a well-described paraneoplastic manifestation encountered in a variety of malignancies. However, it is rarely the initial feature of a neuroendocrine tumor.Herein we report a caseof metastatic pancreatic neuroendocrine tumor (NET)presenting with a refractory hypercalcemia and initially misdiagnosed as an adenocarcinoma of the pancreas.Objective: The aim of this case report is to illustratesome of thecom...

ea0029oc7.1 | Adrenal Clinical | ICEECE2012

Progression-free survival without treatment of malignant pheochromocytoma and paraganglioma at one year

Hescot S. , Leboulleux S. , Amar L. , Borget I. , Vezzosi D. , Libe R. , Niccoli P. , Borson-Chazot F. , Do Cao C. , Tabarin A. , de la Fouchardiere C. , Raingeard I. , Chougnet C. , Gimenez-Roqueplo A. , Young J. , Bertherat J. , Wemeau J. , Bertagna X. , Schlumberger M. , Plouin P. , Baudin E.

Pheochromocytoma and paraganglioma are defined as malignant by the occurence of metastasis in extra paraganglionic sites. The natural evolution of these tumors remains unknown.The aim of our retrospective study was to define the progression-free survival (PFS) of untreated Malignant Pheochromocytoma and Paraganglioma (MPP) at 12 months (12 m-PFS) and to look for prognostic markers of 12 m-PFS. We analyzed clinical parameters of patients followed within 8...